Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab + fulvestrant + palbociclib
- Development stage
- Phase 2
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
A combination therapy consisting of avelumab (a PD-L1 inhibitor), fulvestrant (an estrogen receptor antagonist), and palbociclib (a CDK4/6 inhibitor). This triple combination is being investigated for the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer in patients who have progressed on prior endocrine therapy and CDK4/6 inhibitors.
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ESR1 (ERα)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on avelumab + fulvestrant + palbociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab + fulvestrant + palbociclib.